Results 201 to 210 of about 1,822,518 (269)

Portuguese Pancreatic Club Perspective on Epidemiology, Classification, and Natural History of Pancreatic Intraductal Papillary Mucinous Neoplasms. [PDF]

GE Port J Gastroenterol
Bravo AC, Cruz R, Fernandes A, Bispo M, Vilas-Boas F, Gonçalves TC, Rodrigues-Pinto E, Fidalgo C.   +7 more
europepmc   +1 more source

LDAcoop: Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro

Molecular Oncology, EarlyView.
Limiting dilution assays (LDAs) quantify clonogenic growth by seeding serial dilutions of cells and scoring wells for colony formation. The fraction of negative wells is plotted against cells seeded and analyzed using the non‐linear modeling of LDAcoop.
Nikko Brix, Daniel Samaga, Katharina Gehr, Benedek Dankó, Mohamed Schumann, Guido Drexler, Ahmed Alnatsha, Georg Beyer, Ujjwal Mahajan, Martin Selmansberger, Julia Mayerle, Claus Belka, Horst Zitzelsberger, Kirsten Lauber   +13 more
wiley   +1 more source

Trends in Childhood and Adolescent Cancer Incidence Rates in the United States between 2001 and 2022. [PDF]

Cancer Discov
Shiels MS, Haque AT, Jones RR, Kitahara CM, Glod JW, Widemann BC, Morton LM, Chanock SJ, Savage SA.   +8 more
europepmc   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

C-Cell Carcinoma in a Common Marmoset (Callithrix jacchus) With a Brief Review of Thyroid Neoplasms in Neotropical Primates. [PDF]

J Med Primatol
de Macêdo IL, Gottdenker NL, Oliveira LJ, de Sousa DER, da Fonseca YNG, Cerqueira LA, Borges BP, de Castro MB.   +7 more
europepmc   +1 more source

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

Summarizing relationships between chemicals, genes, proteins, and diseases in PubChem using analysis of their co-occurrences in patents. [PDF]

J Cheminform
Zaslavsky L, Cheng T, Gindulyte A, Kim S, Thiessen PA, Bolton EE.   +5 more
europepmc   +1 more source

Infrared laser sampling of low volumes combined with shotgun lipidomics reveals lipid markers in palatine tonsil carcinoma

Molecular Oncology, EarlyView.
Nanosecond infrared laser (NIRL) low‐volume sampling combined with shotgun lipidomics uncovers distinct lipidome alterations in oropharyngeal squamous cell carcinoma (OPSCC) of the palatine tonsil. Several lipid species consistently differentiate tumor from healthy tissue, highlighting their potential as diagnostic markers.
Leonard Kerkhoff, Manuela Moritz, Dennis Eggert, Anna Worthmann, Joerg Heeren, Henrike Zech, Till S. Clauditz, Waldemar Wilczak, Hartmut Schlüter, Christian S. Betz, Arne Böttcher, Jan Hahn   +11 more
wiley   +1 more source

Characterization of chromosome 5 aberrations in TP53 mutated myeloid neoplasms with ≥5% blasts: An International TP53 Investigators Network (iTiN) study [PDF]

Irfan Yasin, Anna Stengel, Haipeng Shao, Amandeep Kaur, Emily F. Mason, Pranav Pramod Patwardhan, Nathanael G. Bailey, Sharmila Ghosh, Kedar Inamdar, Anand Patel, Madhavi Pandiri, Jingjing Zhang, Payal Sojitra, Hamza Tariq, Zenggang Pan, Danica Wiredja, Peng Wang, Melissa Y. Tjota, Jeremy Segal, Hong Chang, David A. Sallman, Daniel A. Arber, Ayalew Tefferi, Talha Badar, Anamarija M. Perry, Claudia Haferlach, Angela M. Lager, Girish Venkataraman   +27 more
openalex   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source